ACC 2022 – Astra’s cholesterol lowerer surprise comes just a little late

A little-known antisense oligonucleotide, Astrazeneca/Ionis’s AZD8233, has surprised in a mid-stage trial, showing cholesterol lowering well in excess of Amgen and Sanofi/Regeneron’s anti-PCSK9 MAbs and Novartis’s RNAi therapy Leqvio. 50mg once monthly, the middle of three AZD8233 doses tested in the Etesian study, prompted 73% LDL cholesterol reduction from baseline at 12 weeks, the ACC meeting heard yesterday.